BusinessBiothera Pharmaceuticals Presents Translational Data from Ongoing Clinical Trials Showing Imprime PGG in Combination with Merck’s KEYTRUDA® (pembrolizumab) Drives Innate and Adaptive Immune Responses in TumorsBy Nasdaq OMXApr 16, 2018, 1:01 PM UTC
BusinessBiothera Pharmaceuticals Commences Phase 2 Head and Neck Cancer Study Evaluating Combination of Imprime PGG and Merck’s KEYTRUDA® (pembrolizumab)By Nasdaq OMXFeb 6, 2018, 2:30 PM UTC
BusinessBiothera Pharmaceuticals Enters Cancer Immunotherapy Clinical Trial Collaboration AgreementBy Nasdaq OMXNov 28, 2017, 2:01 PM UTC
BusinessBiothera Pharmaceuticals to Present at the 29th Annual Piper Jaffray Healthcare ConferenceBy Nasdaq OMXNov 21, 2017, 2:23 PM UTC
BusinessBiothera Pharmaceuticals Presents Data Broadening Imprime PGG Mechanism of ActionBy Nasdaq OMXNov 13, 2017, 2:30 PM UTC
BusinessBiothera Pharmaceuticals Presents Preclinical Data Showing Imprime PGG Activates Natural Killer Cell-Mediated Tumor KillingBy Nasdaq OMXOct 30, 2017, 1:01 PM UTC
BusinessBiothera Pharmaceuticals Announces Presentations on Imprime PGG at Three Upcoming Healthcare ConferencesBy Nasdaq OMXSep 28, 2017, 4:09 PM UTC
BusinessBiothera Pharmaceuticals Announces Initiation of Phase 1b/2 Clinical Study Evaluating Combination of Imprime PGG and Merck’s KEYTRUDA in Non-Small Cell Lung CancerBy Nasdaq OMXJul 19, 2017, 2:00 PM UTC
